Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Recurrence 1Postoperative Complications 1Peritoneal Neoplasms 1Neoplasm, Residual 1Gastric Adenocarcinoma 1Adrenocortical Carcinoma 1

Interventions

Cyclophosphamide 26fludarabine 18Dexamethasone 17pembrolizumab 12Rituximab 11Etoposide 10venetoclax 9pomalidomide 9Gemcitabine 9fludarabine phosphate 7daratumumab 7Lenalidomide 7Bortezomib 7carfilzomib 6obinutuzumab 5glofitamab 5Vincristine 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Doxorubicin 4Cytarabine 4Carboplatin 4zanubrutinib 3ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Cytoreduction Surgical Procedures × 90 days × Clear all
NCT07567573 2026-05-05

retroESGO ov1

European Society of Gynaecological Oncology

Completed
11,383 enrolled
Gynecologic

Ovarian Neoplasms, Postoperative Complications, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡